1. Home
  2. NPT vs ELTX Comparison

NPT vs ELTX Comparison

Compare NPT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Texxon Holding Limited Ordinary shares

NPT

Texxon Holding Limited Ordinary shares

N/A

Current Price

$1.78

Market Cap

64.3M

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

N/A

Current Price

$1.60

Market Cap

63.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NPT
ELTX
Founded
2011
2011
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.3M
63.3M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
NPT
ELTX
Price
$1.78
$1.60
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $13.67
AVG Volume (30 Days)
14.7K
★ 264.8K
Earning Date
11-17-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.29
EPS
★ N/A
N/A
Revenue
N/A
★ $2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.14
$1.44
52 Week High
$22.38
$16.00

Technical Indicators

Market Signals
Indicator
NPT
ELTX
Relative Strength Index (RSI) 36.17 38.75
Support Level $1.23 $1.44
Resistance Level $3.61 $1.98
Average True Range (ATR) 0.21 0.19
MACD 0.03 0.02
Stochastic Oscillator 38.65 31.48

Price Performance

Historical Comparison
NPT
ELTX

About NPT Texxon Holding Limited Ordinary shares

Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: